ATLANTA, March 29, 2005 (PRIMEZONE) -- Market Pulse News Alert for this AM, Stocks to Watch are: BioCurex, Inc. (Pink Sheets:BOCX), Digital Impact, Inc. (Nasdaq:DIGI), Yahoo! Inc. (Nasdaq:YHOO), and SunGard Data Systems, Inc. (NYSE:SDS).
Investors need to be watching BioCurex, Inc. (Pink Sheets:BOCX) this AM! BioCurex, Inc. is a leading edge biotechnology company with proprietary and patented technologies in the areas of cancer diagnosis, imaging and therapy. Results have consistently proven that BioCurex successfully detects over 90% of all cancers in blood or tissue samples--levels significantly above any present method. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. BioCurex Inc. is currently developing and commercializing cancer diagnostic products based upon their breakthrough RECAF(tm) cancer marker technology! BioCurex had great news out in a press release before today's opening bell regarding Abbott and BioCurex today announcing they have entered into a licensing agreement for BioCurex's RECAF(tm) material and technology! Investors should be watching this one closely!
Abbott and BioCurex (Pink Sheets:BOCX) today announced they have entered into a licensing agreement for BioCurex's RECAF(tm) material and technology. The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
"Because many cancer deaths may be prevented with early screening and treatment, it's important to develop new cancer tests that could more effectively target a specific type of cancer. Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott. "Abbott's goal is to further develop this technology, incorporating it into future tests on our ARCHITECT(r) system, for use in cancer diagnosis and monitoring."
Under terms of the agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology. The agreement includes payment to BioCurex of up-front fees, product development milestones and royalties on any product sales. Other terms of the agreement were not disclosed.
"In terms of cancer detection and treatment, our RECAF technology has the potential to improve patient care due to its ability to differentiate cancer cells from healthy cells. Abbott is a worldwide leader in diagnostic testing, and we're very excited to be able to work with them on implementing this technology with Abbott's instruments for use in future cancer tests," said Ricardo Moro, M.D., chief executive officer, BioCurex.
According to the World Health Organization, more than 10 million people are diagnosed with cancer every year, and it is estimated that there will be 15 million new cases every year by 2020. The chance of cure increases substantially if cancer is detected early.
About BioCurex
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the area of cancer diagnosis, imaging and therapeutics. To find out more about BioCurex (Pink Sheets:BOCX), visit www.biocurex.com.
About Abbott
Abbott has a strong history in cancer diagnostics. In 1991, Abbott developed the first automated PSA test for use on the IMx(r) System and has continued to expand cancer test menus across its diagnostic analyzers. Abbott's innovative genomic tests include Vysis(r) UroVysion, which aids in diagnosing and monitoring bladder cancer, and PathVysion(r), for detecting amplification of the HER-2 gene to aid in determining whether a patient is an appropriate candidate for Herceptin(r) (trastuzumab) therapy for breast cancer.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 60,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Stocks in the news and acting well as of late include: Digital Impact, Inc. (Nasdaq:DIGI), Yahoo! Inc. (Nasdaq:YHOO), and SunGard Data Systems, Inc. (NYSE:SDS).
Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.
You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated twenty five thousand dollars from a third party shareholder for its coverage of BioCurex, Inc. MP also has fifty thousand restricted shares pending from BioCurex, Inc. In addition, MP in the open market previously purchased ten thousand shares of stock in BioCurex, Inc. for a total purchase price of fourteen thousand eighty dollars. To date, MP has sold zero shares. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market Pulse News Alert is a division of MP.